Beware of thromboembolic risk in obese patients on direct oral anticoagulants (DOACs).
暂无分享,去创建一个
[1] A. Medford,et al. Lesson of the month 2: Pulmonary embolism in a patient on rivaroxaban and concurrent carbamazepine. , 2018, Clinical medicine.
[2] P. Sandset,et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH , 2016, Journal of thrombosis and haemostasis : JTH.
[3] S. Hatipoglu,et al. A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough? , 2015, Anatolian journal of cardiology.
[4] C. Frost,et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. , 2013, British journal of clinical pharmacology.